Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.
Overview
After several years of poor performance, Bristol Myers Squibb (NYSE: BMY) is bouncing back. The company's shares are up 42% over the trailing 12-month period, while the S&P 500 has climbed just 15%. Could there be more upside ahead for the pharmaceutical giant? There are some reasons to think so. Bristol Myers is trading at just 9.4x forward earnings, versus an average of 18.5x for healthcare stocks.
Is Bristol Myers a great value play to buy now?
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.